Longboard Pharmaceuticals, Inc.

General Information
Business:

We are a clinical-stage biopharmaceutical company focused on developing novel transformative medicines for neurological diseases. We were formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Our small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Our pipeline includes:

*LP352, an oral centrally acting 5-hydroxytryptamine 2c receptor subtype (5-HT2c) super agonist, to treat developmental and epileptic encephalopathies (DEEs), including Dravet syndrome and Lennox-Gastaut syndome; this drug candidate is in a Phase 1 clinical trial, and we expect to initiate a Phase 1b/2a clinical trial in the first quarter of 2022;

*LP143, a centrally active full cannabinoid Type 2 receptor (CB2) agonist in IND-enabling studies to treat neurodegenerative diseases associated with neuroinflammation caused by microglial activation, including amyotrophic lateral sclerosis (ALS), and

*LP659, a centrally acting sphingosine-1 phosphate (S1P) receptor subtypes 1 and 5 (S1P1,5) modulator in IND-enabling studies for central nervous system (CNS) neuroinflammatory diseases. 

(IND stands for investigational new drug, a type of FDA application and authorization.)

(Note: Longboard Pharmaceuticals priced its IPO on March 10, 2021: 5 million shares at $16 – the high end of its $14-to-$16 range – to raise $80 million.)

Industry: Pharmaceuticals
Employees: 6
Founded: 2020
Contact Information
Address 6154 Nancy Ridge Drive San Diego, California 92121
Phone Number (619) 592-9775
Web Address http://www.longboardpharma.com/
View Prospectus: Longboard Pharmaceuticals, Inc.
Financial Information
Market Cap $253.8mil
Revenues $0 mil (last 12 months)
Net Income $-14.4 mil (last 12 months)
IPO Profile
Symbol LBPH
Exchange NASDAQ
Shares (millions): 5.0
Price range $16.00 - $16.00
Est. $ Volume $80.0 mil
Manager / Joint Managers Citigroup/Evercore ISI/Guggenheim Securities/Cantor
CO-Managers -
Expected To Trade: 3/12/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change